Used in research as a potent and selective inhibitor of anaplastic lymphoma kinase (ALK), particularly in the development of targeted cancer therapies. Shows promising activity against ALK-positive non-small cell lung cancer (NSCLC) by blocking abnormal signaling pathways that drive tumor growth. Also demonstrates effectiveness in overcoming resistance mutations in ALK, making it valuable in second-generation inhibitor design. Investigated for its blood-brain barrier penetration, supporting potential use in treating brain metastases associated with ALK-driven cancers. Currently utilized primarily in preclinical studies and drug development rather than clinical treatment.